Skip to main content
Top
Published in: Breast Cancer Research 1/2015

Open Access 01-12-2015 | Erratum

Erratum to: Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers

Authors: Shandong Wu, Susan P. Weinstein, Michael J. DeLeo, Emily F. Conant, Jinbo Chen, Susan M. Domchek, Despina Kontos

Published in: Breast Cancer Research | Issue 1/2015

Login to get access

Excerpt

With this erratum, we would like to clarify key differences between our current publication [1], and prior work published in the American Journal of Roentgenology (AJR) and cited as reference [33] (reference [2] here), from which our current study includes a subset of the patient population. First, this prior work was a qualitative reader study, in which fibroglandular tissue (FGT) and background parenchymal enhancement (BPE) were evaluated subjectively using visual assessment by two clinical readers into the four qualitative Breast Imaging Reporting and Data System (BI-RADS) categories. In contrast, in our study published in Breast Cancer Research (BCR), we performed quantitative analysis, using a fully-automated computerized method developed by our group, reported for the first time for quantifying BPE in breast MRI, where a key aspect for BPE quantification, the optimal evaluation and determination for the parameter of enhancement ratio (R%), was also investigated in association to patient cancer outcomes. In addition to evaluating group-wise changes in the means of FGT and BPE between pre- and post- risk-reducing salpingo-oophorectomy (RRSO), we also included a comparison of the effect for BPE assessed in three sequential post-contrast sequences acquired at different time-points, and most importantly conducted an additional evaluation of predicting development of breast cancer after RRSO, using the quantitative changes of the FGT and BPE measures post RRSO, which was not evaluated in the AJR study. This is a key investigation, as predicting subsequent breast cancer is the main outcome of interest for improving clinical-decision making for risk-evaluation and risk-reduction management of women with BRCA mutations. The quantitative analysis reported in our study published in BCR has shown overall superior performance to the prior qualitative study published in AJR, providing a potential precision-medicine approach for the quantification of MRI BPE as a biomarker for guiding risk-reduction management in women at high-risk for breast cancer. …
Literature
1.
go back to reference Wu S, Weinstein SP, DeLeo 3rd MJ, Conant EF, Chen J, Domchek SM, et al. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast Cancer Res. 2015;17:67.CrossRefPubMedPubMedCentral Wu S, Weinstein SP, DeLeo 3rd MJ, Conant EF, Chen J, Domchek SM, et al. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast Cancer Res. 2015;17:67.CrossRefPubMedPubMedCentral
2.
go back to reference DeLeo MJ 3rd, Domchek SM, Kontos D, Conant E, Chen J, Weinstein S. Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy. Am J Roentgenol. 2015;204(3):669–73.CrossRef DeLeo MJ 3rd, Domchek SM, Kontos D, Conant E, Chen J, Weinstein S. Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy. Am J Roentgenol. 2015;204(3):669–73.CrossRef
Metadata
Title
Erratum to: Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers
Authors
Shandong Wu
Susan P. Weinstein
Michael J. DeLeo
Emily F. Conant
Jinbo Chen
Susan M. Domchek
Despina Kontos
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2015
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-015-0651-7

Other articles of this Issue 1/2015

Breast Cancer Research 1/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine